Trials / Conditions / Stage IVA Verrucous Carcinoma of the Larynx

Stage IVA Verrucous Carcinoma of the Larynx

20 registered clinical trials studyying Stage IVA Verrucous Carcinoma of the Larynx — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Terminated	Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer NCT02177838	Rutgers, The State University of New Jersey	N/A
Completed	Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No NCT02245100	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	—
Completed	Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell C NCT02035527	Ohio State University Comprehensive Cancer Center	Phase 1
Completed	Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoi NCT02123511	Mayo Clinic	Phase 2
Withdrawn	Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Ra NCT01728480	Roswell Park Cancer Institute	Phase 1
Completed	Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Sta NCT02048020	Jonsson Comprehensive Cancer Center	Phase 2
Withdrawn	Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiatio NCT01674374	Roswell Park Cancer Institute	Phase 2
Completed	PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT01816984	University of Chicago	Phase 1 / Phase 2
Terminated	Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137	Stanford University	Phase 1
Completed	TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squam NCT01334177	University of Washington	Phase 1
Completed	Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab NCT00939627	National Cancer Institute (NCI)	Phase 2
Recruiting	Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck NCT01473784	Ohio State University Comprehensive Cancer Center	N/A
Completed	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. NCT01469429	Ohio State University Comprehensive Cancer Center	Phase 1 / Phase 2
Completed	Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00513435	National Cancer Institute (NCI)	Phase 2
Completed	Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00507767	National Cancer Institute (NCI)	Phase 2
Completed	Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer NCT00114283	National Cancer Institute (NCI)	Phase 2
Completed	S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00096512	National Cancer Institute (NCI)	Phase 2
Completed	Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497	National Cancer Institute (NCI)	N/A
Completed	Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck NCT00033618	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer NCT00049283	National Cancer Institute (NCI)	Phase 1